Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Discontinued Operations (Tables)

Note 11 - Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2016

Notes Tables

Schedule of Components of Loss from Discontinued Operations [Table Text Block]

		Three Months Ending June 30,								Six Months Ending June 30,
		2016				2015				2016				2015
Revenue, net		$	-			$	34,087			$	1,644			$	70,549

Income (loss) from discontinued operations			144				1,512				(592	)			4,039
Gain (loss) on sale of assets			1,326				-				1,326				217
Income from discontinued operations, before tax			1,470				1,512				734				4,256
Income tax expense			291				1				336				3
Income from discontinued operations, net of tax		$	1,179			$	1,511			$	398			$	4,253

Discontinued Operation, Schedule of Amounts Recognized in Balance Sheet [Table Text Block]

		For the Six Months Ended June 30, 2016												For the Year Ended December 31, 2015
		CSO				DCA/ TVG				Total				CSO				DCA/ TVG				Total
Accounts receivable, net			-				-				-				3,296				-				3,296
Unbilled receivable, net			-				-				-				16				-				16
Other			477				150				627				2,062				-				2,062
Current assets from discontinued operations			477				150				627				5,374				-				5,374
Property and equipment, net			-				-				-				190				-				190
Other			-				-				-				-				150				150
Long-term assets from discontinued operations			-				-				-				190				150				340
Total assets			477				150				627				5,564				150				5,714

Accounts payable			744				-				744				3,767				-				3,767
Unearned contract revenue			-				-				-				11				-				11
Accrued salary and bonus			1,925				-				1,925				3,036				-				3,036
Other			2,358				219				2,577				5,092				358				5,450
Current liabilities from discontinued operations			5,027				219				5,246				11,906				358				12,264
Total liabilities			5,027				219				5,246				11,906				358				12,264